The American patent system innovation framework was built on a simple bargain: disclose your invention to the public, and the government grants you a temporary monopoly. This arrangement, enshrined in the Constitution itself, aimed to fuel progress by rewarding inventors while ensuring their discoveries eventually benefit everyone. Two hundred and thirty-six years later, that bargain has inverted. The system designed to promote innovation now frequently blocks it.
This isn’t a complaint about patents existing. Patents serve a legitimate function. The problem is that the patent system innovation mechanism has been captured by entities whose business model depends not on creating anything, but on extracting value from those who do. The numbers tell the story: in the tech sector, more than 85% of patent lawsuits are filed by companies that produce no products or services[s]. The median patent lawsuit isn’t filed by an inventor. It’s filed by an anonymous LLC.
The Original Bargain
The Constitution grants Congress the power “To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries.”[s] Note what comes first: promoting progress. The exclusive right is the mechanism, not the goal.
When Congress passed the first Patent Act in 1790, the first Patent Board included Thomas Jefferson, who served as the nation’s first patent examiner[s]. Jefferson was skeptical of monopolies but understood their utility for spurring invention. The first U.S. patent went to Samuel Hopkins for a process of making potashA potassium-rich mineral compound used as a major agricultural fertilizer. Belarus and Canada are among the world's largest producers., an ingredient used in fertilizer. It was practical, specific, and disclosed a genuine advance.
The patent system innovation model worked roughly as intended for two centuries. Patents expired, knowledge entered the public domainThe legal status of creative works no longer protected by copyright, making them freely available for anyone to use, modify, or redistribute without permission., competitors built upon it. Then the economics changed.
Patent TrollsCompanies that acquire patents solely to sue other companies for infringement, rather than creating products or services themselves.: The Innovation Tax
In 2025, patent litigation increased by 20%, driven almost entirely by non-practicing entities[s]. These companies, often called patent trolls, don’t make anything. They acquire patents, frequently broad and vague ones that survived examination years ago, and sue companies that actually build products.
The business model exploits litigation economics. Defending a patent lawsuit costs an average of $4 million[s]. For smaller cases where damages are under $1 million, litigation still costs around $700,000 to $900,000 per patent[s]. So the troll offers to settle for $200,000. Pay the nuisance fee or spend twenty times that amount in court with no guarantee of winning. Most companies pay.
More than 52% of companies targeted by these lawsuits between 2017 and 2022 had annual revenues under $25 million[s]. Patent trolls don’t primarily sue deep-pocketed tech giants who can afford to fight. They target small businesses that can’t. For a company earning $10 million annually, a $4 million legal battle represents an existential threat regardless of the lawsuit’s merits.
Pharmaceutical Patent System Innovation Abuse
Drug patents present an even starker case of the patent system innovation framework being weaponized against its stated purpose. The original deal was clear: develop a new medicine, get 20 years of exclusivity to recoup your research investment, then generics enter and prices fall. That’s not what happens.
Drug companies file, on average, more than 140 patent applications per drug. Sixty-six percent of those applications are filed after FDA approval[s]. The tactic is called evergreeningA pharmaceutical strategy of filing secondary patents on minor modifications to extend exclusivity beyond the original patent expiration.: file patents on minor modifications, extended-release formulations, different salts of the same molecule, new dosing regimens, even packaging. Each patent creates litigation risk for generic manufacturers.
AbbVie’s Humira demonstrates the strategy at industrial scale. The company filed over 250 patent applications for a single drug, receiving approval for 130 patents. Ninety percent of these applications came after Humira was already on the market[s]. The original compound patent expired in 2016. Biosimilar competition didn’t arrive in the United States until 2023, during which time Humira generated tens of billions in revenue at monopoly prices.
The contrast with other countries is instructive. BiosimilarsGeneric versions of biological drugs that are highly similar to an already approved biological medicine. face nine to twelve times more patent assertions in the United States than in Canada or the United Kingdom[s]. The molecule is the same. The science is the same. American patients simply pay more because American patent law permits more aggressive blocking strategies.
The Billion-Dollar Design Patent
The smartphone patent wars showed what happens when the patent system innovation disputes involve products used by billions. In 2012, Apple won a $1.049 billion verdict against Samsung[s]. Among the infringed patents: the “bounce-back effect” when scrolling, “tap to zoom” functionality, and design patents covering “rounded corners and tapered edges”[s].
The case eventually reached the Supreme Court and settled confidentially in 2018. But the broader smartphone patent conflict involved over 1,100 cases filed globally by the top ten manufacturers. By 2012, Apple and Samsung alone were litigating in more than 50 lawsuits worldwide, with billions of dollars in claimed damages between them.
Whatever intellectual property was genuinely at stake, the resources poured into patent system innovation litigation were resources not spent on building better products. Every dollar a company allocates to patent lawyers is a dollar not allocated to engineers. The system meant to reward innovation became a tax on it.
The Counterargument and Its Limits
Defenders of the current patent system innovation regime make reasonable points. Some secondary patents reflect genuine improvements. Extended-release formulations that improve patient adherence represent real value. Design patents protect legitimate investment in product aesthetics. The threat of infringement lawsuits creates incentives to develop truly novel technologies rather than copying competitors.
Academic research offers some support for this view. One study found that generic drugs enter the market roughly when expected despite extensive secondary patenting, suggesting that evergreening strategies don’t systematically delay competition. Generic manufacturers are sophisticated actors who successfully challenge weak patents. Between 2000 and 2019, generic challengers won approximately 73% of fully litigated patent cases.
But aggregate statistics obscure the distribution. The drugs with the largest patent portfolios, the most aggressive litigation strategies, and the most revenue are precisely the drugs where blocking tactics work. Saying evergreening “doesn’t work on average” is like saying blizzards don’t significantly reduce annual average temperature. True at the aggregate level, devastating if you’re the one whose pipes froze.
What Would Jefferson See?
If the first Patent Board reconvened today, they would find a system recognizable in structure but alien in practice. The constitutional language remains: promote progress through limited-time exclusivity. The implementation has drifted.
They would see patents granted on “one finger to scroll, two to pinch and zoom” and wonder how such basic interactions qualify as non-obvious inventions. They would see pharmaceutical companies stacking 250 patents on a single drug and question whether “limited times” means anything when the clock can be reset indefinitely. They would see 85% of tech patent lawsuits filed by entities that manufacture nothing and ask what progress is being promoted.
Reform efforts have had mixed success. The Supreme Court’s 2014 Alice decision made it harder to patent abstract ideas dressed in computer jargon, but patent trolls adapted[s]. Legislative proposals like the Patent Eligibility Restoration Act would roll back even those modest constraints. The FTC has challenged improper pharmaceutical patent listings, but one-off enforcement actions don’t fix structural problems.
The patent system innovation framework needs rebalancing. Higher standards for what qualifies as non-obvious. Faster, cheaper mechanisms for challenging weak patents. Real consequences for filing frivolous infringement claims. Fee-shifting that makes patent trolling economically unviable. None of this requires abandoning the constitutional bargain. It requires actually enforcing it.
The founders understood that monopolies are dangerous but sometimes useful. They created a system to harness that danger for public benefit. When the system instead extracts billions from actual innovators to enrich entities that create nothing, something has gone wrong. The fix isn’t complicated. It’s a matter of political will to implement what the Constitution already requires: promoting progress, not protecting rent-seekers.
This article is for informational purposes only and does not constitute professional advice.
